Figure 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
<p>PK profile for EnaV and MMAE in the dose-escalation phase. Plasma/serum concentrations of (<b>A</b>) conjugated EnaV and (<b>B</b>) MMAE at Q3W. Dots indicate observed data; lines indicate mean data. LLOQ, lower limit of quantitation.</p>
Gorde:
| Egile nagusia: | |
|---|---|
| Beste egile batzuk: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Argitaratua: |
2025
|
| Gaiak: | |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|
| Gaia: | <p>PK profile for EnaV and MMAE in the dose-escalation phase. Plasma/serum concentrations of (<b>A</b>) conjugated EnaV and (<b>B</b>) MMAE at Q3W. Dots indicate observed data; lines indicate mean data. LLOQ, lower limit of quantitation.</p> |
|---|